NSE: CIPLA | BSE: 500087

Mid-range Performer

Download real time

1569.60 10.00 (0.64%)

440.7K NSE+BSE Volume

NSE 18 Sep, 2025 1:29 PM (IST)

126,786.9

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Cipla Ltd.

07 Aug 2021

1569.60

0.64%

Cipla (BUY): Strong quarter

Buy: Cipla Ltd.

Target

BOB Capital Markets Ltd.

Q1 revenue/EBITDA grew 27%/28% YoY, beating consensus estimates by 7%/19%

Cipla Ltd. has an average target of 1702.60 from 10 brokers.

Cipla Ltd.

06 Aug 2021

1569.60

0.64%

Q1FY22 Result Update - Core business in-line; Guided for few good launches in H2FY22E - ACCUMULATE

Accumulate: Cipla Ltd.

Target

Prabhudas Lilladhar

South Africa) and better prospects in emerging markets. CIPLA surpassed its guidance of cost saving estimates by Rs4-5bn in FY21 and we believe similar trend to continue in FY22E/23E. Its performance in Q1 was above our estimates given 1) favorable product mix with tailwind in COVID portfolio growth, 2) booster effect on anti-infective portfolio, benefitting peers as well, 3) qualitative improvement in US sales at US$140m and 4) profitable products (in Pvt mkt) aided growth in SA (in CC), despite low tender business. We believe benefits from COVID products to decrease from Q2FY22E, given...

Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.

Cipla Ltd.

06 Aug 2021

1569.60

0.64%

Cipla Limited

Results Update: Cipla Ltd.

SMC online

Cipla Q1FY22, Net profit jumps to Rs 715 crore, beats estimates Pharma For the quarter ending June 2021, consolidated net sales (including other operating income) of Cipla has increased 26.65% to Rs 5504.35 crore compared to quarter ending june 2020. Sales of Phamaceuticals segment has gone up 26.21% to Rs 5,384.22 crore (accounting for 97.21% of total sales). Sales of New Ventures segment has gone up 32.39% to Rs 154.70...

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

06 Aug 2021

1569.60

0.64%

Adding peptide injectables to Respiratory pipeline for US market

Neutral: Cipla Ltd.

Target

Motilal Oswal

Adding peptide injectables to Respiratory pipeline for US market Motilal Oswal values your support in the Asiamoney Brokers Poll 2021...

Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.

Cipla Ltd.

06 Aug 2021

1569.60

0.64%

Cipla

Buy: Cipla Ltd.

Target

ICICI Securities Limited

Indian branded formulations business accounts for ~40% of revenues and enjoys leadership in therapies like respiratory, anti-infective, cardiac, gynaecology & gastro-intestinal Cipla derives 21% of its export revenues from the US followed by 12% from...

Cipla Ltd. has an average target of 1702.60 from 10 brokers.

Cipla Ltd.

12 Jul 2021

1569.60

0.64%

Pick of the Week - Cipla

Buy: Cipla Ltd.

Target

Edelweiss

Cipla is a global pharma company with a geographically diversified presence

Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.

Cipla Ltd.

19 May 2021

1569.60

0.64%

CIPLA LTD

Buy: Cipla Ltd.

Target

Geojit BNP Paribas

Robust COVID portfolio along with a strong chronic portfolio are the key catalysts for Cipla. Continued growth in the US market, healthy margins on reduced costs and an attractive pipeline should support the company's outlook in the upcoming quarters. We reiterate our BUY...

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

17 May 2021, 12:00AM

1569.60

0.64%

Q4FY21 Result Update - Weakness in SA and US play spoilsport to cost savings benefits - Accumulate

Accumulate: Cipla Ltd.

Recommendation Target

Prabhudas Lilladhar

part of it would continue in FY22E/23E too. Its recent performance in 4Q was below our estimates due to 1) unfavorable product mix with lack of COVID portfolio growth in India, 2) anti-infective portfolio continued to setback lower volume in India, 3) stagnant US sales at around US$140m over four quarters,...

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

16 May 2021

1569.60

0.64%

Avadh Sugar

Buy: Cipla Ltd.

Target

ICICI Securities Limited

Q4 revenues grew 5.3% YoY to | 4606 crore. Domestic sales grew 4.5% YoY to | 1807 crore. US grew 17.1% YoY to | 1002 crore on the back of continued Albuterol ramp-up. RoW markets business de-grew 4.8% YoY to | 674 crore. South Africa business grew 13.9% YoY to | 606 crore tracking strong private business momentum. EBITDA margins expanded 281 bps YoY (down 653 bps QoQ) to 17.3% mainly due to significantly lower other expenditure partially offset by lower gross margins. Subsequently, EBITDA grew 25.7%...